演題抄録

ポスター

開催概要
開催回
第56回・2018年・横浜
 

切除不能メラノーマにおける抗PD-1抗体薬の中止時期について

演題番号 : P108-1

[筆頭演者]
演者)吉川 周佐:1 
[共同演者]
大塚 正樹:1、杉原 悟:1、清原 祥夫:1

1:静岡県立静岡がんセンター・皮膚科

 

As of January 2018, anti-PD-1 antibody drugs have been used for approximately 2,500 cases of melanoma since nivolumab was approved for nonresectable melanoma July 2014. As many examples are effective responses are reported, currently, there is no clear answer to the question on how long to continue the administration when the effective response is being maintained.
Until February 2018, this hospital has administered to 85 patients with unresectable melanoma patients. In terms of the effect, overall response rate (ORR) of about 20% and disease control rate (DCR) of about 48% have been achieved, showing relatively good progress. However, up to about 70% of patients had to discontinue administration due to various reasons. The progression of tumor is the main reason, but there are quite a few discontinuities due to side effects. In case of discontinuation due to a side effect, there is an inevitable reality that most cases had to discontinue while showing good responses. When examining these cases of cessation due to side effects, it seemed that the response period tended to persist after withdrawal after long-term administration compared to the cases of short-term administration. This time we will report cases where anti-PD-1 antibody-drug administration was discontinued while showing responses during the treatment that we conducted at our hospital. We state the considerations about the time to stop administration while good response is present

キーワード

臓器別:皮膚

手法別:免疫療法

前へ戻る